Commercial

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

BioSpace

Sanofi's interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent's patents had anything to do with the departure of CEO Paul Hudson.

Commercial Immunology & Inflammation Read full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

BioSpace

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.

Commercial Immunology & Inflammation Read full story

Related Stories

CVS obesity drug deal puts Lilly on equal footing with Novo

Kardigan targets IPO to support cardiology pipeline progression

Lilly UK recruits ex-England cricketer as obesity champion

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise